Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,387.04
(
0.29%
)
US TECH 100
22,545.60
(
0.19%
)
Dow Jones
45,434.18
(
0.59%
)
Brent Oil
107.60
(
-0.61%
)
Bitcoin
67,306.02
(
2.04%
)
News Focus
News Focus
Post# of 257306
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 54
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: mcbio post# 105956

Friday, 10/08/2010 7:11:42 PM

Friday, October 08, 2010 7:11:42 PM

Post# of 257306
BCa isn't my best area, but a couple of observations...

600mg bid is a LOT of drug. It will be interesting to see how this performs in broader patient populations.

They have a future trial design problem trying to figure out how to deal with T-DM1 in terms of choosing a path to approval. What have they guided for their next trial indication and design?

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today